{"id":12885,"date":"2026-04-21T06:47:46","date_gmt":"2026-04-21T10:47:46","guid":{"rendered":"https:\/\/www.packagingindustrynews.com\/?p=12885"},"modified":"2026-04-21T06:47:46","modified_gmt":"2026-04-21T10:47:46","slug":"sanisure-adds-petg-to-pharmatainer-range","status":"publish","type":"post","link":"https:\/\/www.packagingindustrynews.com\/?p=12885","title":{"rendered":"SaniSure adds PETG to PharmaTainer range"},"content":{"rendered":"


\n<\/p>\n

\n
\n
\n \n <\/picture>
PETG products are designed as a direct replacement for legacy PETG bioprocessing bottles. Credit: SaniSure \/ Business Wire.<\/figcaption><\/figure>\n<\/p><\/div>\n

SaniSure has introduced PETG PharmaTainer, a bioprocessing bottle and carboy line made with medical-grade Eastman Eastar PETG 6763 resin and the company\u2019s production process and automated manufacturing systems.<\/p>\n

The addition broadens the existing PharmaTainer portfolio, which already includes polyethylene terephthalate (PET) and polycarbonate (PC), by bringing in PETG as another material option.<\/p>\n

\n
\n
\"\"\/<\/figure>\n

Discover B2B Marketing That Performs <\/h4>\n

\n\t\t\t\t\t\tCombine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.\n\t\t\t\t\t<\/p>\n


\n\t\t\t\t\t\t\tFind out more <\/svg><\/span><\/a><\/p>\n<\/section>\n<\/div>\n

The range will be offered in sizes from 10ml stability vials up to 10l carboys, with sterile gamma-irradiated and non-irradiated versions.<\/p>\n

The products are intended for use across bioprocessing stages.<\/p>\n

Standard and custom assemblies using Cap2V8 closures and Cellgyn TPE tubing will be available for open and closed operations.<\/p>\n

The same platform can be used from early research and development through clinical and commercial stages, avoiding requalification during scaling.<\/p>\n

The PETG PharmaTainer line carries the same cleanliness and compliance characteristics as its PET and PC bottle products.<\/p>\n

These include particle levels certified at less than 5% of USP <788> limits for sub-visible particulates, with testing carried out at lot release and no post-wash step required.<\/p>\n

It also reported endotoxin results below the 0.001 EU\/ml detection limit under USP <85>, along with RNase\/DNase-free certification for use in nucleic acid-based therapies such as mRNA, oligonucleotides and gene therapy.<\/p>\n

According to SaniSure, sterile products in the range are gamma sterilised to SAL 10\u207b\u2076.<\/p>\n

This reduces the washing, depyrogenation and sterilisation steps often needed for comparable products.<\/p>\n

The line has been validated for freeze-thaw use down to \u221280\u00b0C for applications including bulk drug substance cold chain, stability studies and frozen intermediates.<\/p>\n

PETG products are designed as a direct replacement for legacy PETG bioprocessing bottles, with matching volume and format specifications.<\/p>\n

The company added that a comparability guide and technical support will be available.<\/p>\n

SaniSure CEO Steven Chevillotte said: \u201cWith PETG PharmaTainer, we are shifting cleanliness from a post-processing step to a fully automated, built-in standard \u2013 enabling us to confidently deliver the cleanest bioprocessing containers on the market for our customers\u2019 most critical applications. <\/p>\n

\u201cOur bottles provide the lowest possible levels of particulates, endotoxins and RNase\/DNase \u2013 by design \u2013 while minimising adoption timelines.\u201d<\/p>\n

<\/p>\n

<\/p>\n

\n